Showing results (2221-2230 of 3,888) with videos related to
Sort By:
Pageof 389
Cancer Biology & Therapy|August 23, 2017
BRAF mutation as a novel driver of eosinophilic cystitisMichael Y Choi, Igor F Tsigelny, Amelie Boichard, et al.Cancer Biology & Therapy|December 9, 2017
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinibLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.Cancer Biology & Therapy|March 6, 2018
Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulationJing Liu, Liguo Feng, Haitao Zhang, et al.Cancer Biology & Therapy|November 15, 2002
EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insightsMarc LadanyiCancer Biology & Therapy|November 15, 2002
The role of ubiquitin-proteasome pathway in oncogenic signalingSerge Y FuchsCancer Biology & Therapy|November 15, 2002
Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cellsRobert McKinstry, Liang Qiao, Adly Yacoub, et al.Cancer Biology & Therapy|November 15, 2002
The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cellsThomas C Chen, Pia Wadsten, Susan Su, et al.Cancer Biology & Therapy|July 25, 2003
Rapamycins: mechanism of action and cellular resistanceShile Huang, Mary-Ann Bjornsti, Peter J HoughtonCancer Biology & Therapy|July 25, 2003
Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapyPaul S Mischel, Stanley F Nelson, Timothy F CloughesyCancer Biology & Therapy|July 25, 2003
Bisindolylmaleimide IX Induces Reversible and Time-Dependent Tumor Necrosis Factor Receptor Family-Mediated Caspase Activation and Cell DeathOskar W Rokhlin, Michael B CohenPageof 389